<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="other" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">INO</journal-id>
<journal-id journal-id-type="hwp">spino</journal-id>
<journal-title>InnovAiT</journal-title>
<issn pub-type="ppub">1755-7380</issn>
<issn pub-type="epub">1755-7399</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1755738013488284</article-id>
<article-id pub-id-type="publisher-id">10.1177_1755738013488284</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>AKT</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>AKT answer relating to thiazolidinediones</article-title>
</title-group>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2013</year>
</pub-date>
<volume>6</volume>
<issue>4</issue>
<fpage seq="b">255</fpage>
<lpage>255</lpage>
<permissions>
<copyright-statement>Â© The Author(s) 2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="society">Royal College of General Practitioners</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<sec id="sec1-1755738013488276"><title>Answer 57 patients</title>
<p>In this analysis, 376 patients had bladder cancer, and of these, 319 patients had never used a thiazolidinedione. Therefore, the remaining 57 patients had, at some time, used either pioglitazone or rosiglitazone or both.</p>
<p>BMJ 2012;344:e3645</p>
</sec>
</body>
</article>